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Abstract. 
Data on the epidemiology of severe acute respiratory illness (SARI) in adults from low-income, high human 
immunodeficiency virus (HIV) prevalence African settings are scarce. We conducted adult SARI surveillance in 
Blantyre, Malawi. From January 2011 to December 2013, individuals aged  15 years with SARI (both 
inpatients and outpatients) were enrolled at a large teaching hospital in Blantyre, Malawi. Nasopharyngeal 
aspirates were tested for influenza and other respiratory viruses by polymerase chain reaction. We estimated 
hospital-attended influenza-positive SARI incidence rates and assessed factors associated with influenza 
positivity and clinical severity (Modified Early Warning Score > 4). We enrolled 1,126 SARI cases; 163 
(14.5%) were positive for influenza. Human immunodeficiency virus prevalence was 50.3%. Annual incidence 
of hospital-attended influenza-associated SARI was 9.7–16.8 cases per 100,000 population. Human 
immunodeficiency virus was associated with a 5-fold greater incidence (incidence rate ratio 4.91, 95% 
confidence interval [CI]: 3.83–6.32). On multivariable analysis, female gender, as well as recruitment in hot, 
rainy season (December to March; adjusted odds ratios (aOR): 2.82, 95% CI: 1.57–5.06) and cool, dry season 
(April to August; aOR: 2.47, 95% CI: 1.35–4.15), was associated with influenza positivity, whereas influenza-
positive patients were less likely to be HIV-infected (aOR: 0.59, 95% CI: 0.43–0.80) or have viral coinfection 
(aOR: 0.51, 95% CI: 0.36–0.73). Human immunodeficiency virus infection (aOR: 1.86; 95% CI: 1.35–2.56) and 
recruitment in hot, rainy season (aOR: 4.98, 95% CI: 3.17–7.81) were independently associated with clinical 
severity. In this high HIV prevalence population, influenza was associated with nearly 15% of hospital-attended 
SARI. Human immunodeficiency virus infection is an important risk factor for clinical severity in all-cause and 
influenza-associated SARI. Expanded access to HIV testing and antiretroviral treatment, as well as targeted 
influenza vaccination, may reduce the burden of SARI in Malawi and other high HIV prevalence settings. 
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INTRODUCTION 
Pneumonia is an important cause of morbidity and mortality in adults in sub-Saharan 
Africa.
1
 However, the burden of severe respiratory illness and the contribution of influenza 
and other respiratory viruses are not well documented in the region. Lack of diagnostic 
capacity, similarity of influenza presentation with common febrile illnesses such as malaria 
and bacterial pneumonia, and prioritization of other high-burden public health problems are 
likely contributory factors. A recent systematic review concluded that most of the sub-
Saharan African countries had insufficient epidemiological data to develop rational strategies 
for influenza prevention and control.
2
 It is, therefore, unsurprising that although the World 
Health Organization (WHO) recommends seasonal influenza vaccine for high-risk groups, 
such as young children, pregnant women, and Human immunodeficiency virus (HIV)–
infected individuals,
3
 few African countries have implemented these recommendations or 
have national policies.
4
 
Following the 2009 influenza A(H1N1) pandemic, respiratory viral surveillance capacity 
has increased substantially in Africa.
5
 Currently, 23 sub-Saharan African countries contribute 
data to the WHO Global Surveillance and Response System.
6
 Emerging data suggest that 
influenza viruses are frequently detected in mild (6.7–40.4%) and severe (4.6–25.5%) acute 
respiratory presentations in the region
7
 and are associated with a higher mortality compared 
with developed settings because of the high prevalence of HIV infection and other 
comorbidities.
8
 However, only a handful of studies have focused on adults
9,10
 and few have 
comprehensively ascertained HIV status. 
Malawi is a low-income country, ranked 170th of 188 countries in the Human 
Development Index.
11
 Active surveillance for influenza and other respiratory viruses was 
established at a large urban teaching hospital in Malawi in January 2011. In this high HIV 
prevalence and malaria-endemic setting, we aimed to describe the epidemiology and viral 
etiology and factors associated with clinical severity and influenza positivity among 
individuals aged  15 years with severe acute respiratory illness (SARI) during 2011–2013. 
MATERIALS AND METHODS 
Study site and setting. 
Malawi has hot rainy (mean temperature > 22°C and rainfall > 100 mm; December to 
March), cool and dry (mean temperature < 22°C and rainfall < 50 mm; April to August), and 
hot and dry (mean temperature > 22°C and rainfall < 50 mm; September to November) 
seasons. The Queen Elizabeth Central Hospital (QECH) is the only government inpatient 
facility providing free health care to the 1.3 million residents of Blantyre District. 
Consequently, most individuals requiring hospitalization from this community will present to 
QECH. Human immunodeficiency virus prevalence in Blantyre is estimated at 18.2%,
12
 but 
up to 74% of patients admitted to the QECH medical wards are HIV infected.
13
 Malaria is 
endemic in Malawi (peak transmission months January to June), and malaria rapid diagnostic 
test (RDT) positivity is 8% among adult inpatients at QECH.
14
 Lower respiratory tract 
infections are the commonest cause of medical admission at QECH.
13
 There is no national 
influenza vaccination policy in Malawi. A WHO-led influenza A(H1N1)pdm09 vaccine 
campaign targeting health-care workers and pregnant women occurred in 2010.
15
 
Study procedures. 
Patients aged 15 years and older presenting to the QECH Emergency Department during 
surveillance hours (8 AM to 3 PM on weekdays) were screened for study eligibility. 
Consecutive patients from the start of the day fulfilling the SARI case definition were 
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recruited (maximum four per day). Study staff collected demographic, clinical, and risk factor 
information using structured questionnaires and obtained nasopharyngeal aspirates and blood 
specimens for malaria and HIV testing. 
SARI was defined as 1) an acute respiratory illness with symptom onset < 7 days, 2) 
reported or recorded fever ( 38°C), 3) cough or sore throat, and 4) shortness of breath or 
difficulty breathing. In our resource-limited setting, patients with severe illness requiring 
admission were often sent home. Therefore, hospital attendance (not admission) was required 
for study enrolment. 
Laboratory procedures. 
The processing of respiratory specimens has been described previously.
16
 In brief, 
nasopharyngeal aspirates were stored at 80°C in Universal Transport Medium (Copan, 
Brescia, Italy). These were batch-tested for influenza A and B by real-time reverse 
transcription–polymerase chain reaction (rRT-PCR) using the CDC human influenza reverse 
transcription–PCR diagnostic panel (CDC Influenza Division, 
http://www.cdc.gov/ncird/flu.html). Influenza-positive specimens were subtyped using the 
CDC rRT-PCR protocol. The FTD respiratory pathogens 33 kit (Fast-track Diagnostics Ltd., 
Luxembourg, http://www.fast-trackdiagnostics.com) was used to detect coronaviruses OC43, 
NL63, HKU1, and 229E; parainfluenza viruses 1–4; respiratory syncytial viruses (RSV) A 
and B; enterovirus; human metapneumovirus; rhinovirus; adenovirus; and bocavirus. 
Samples with a Ct value < 40 were recorded as positive. 
Human immunodeficiency virus testing (Alere Determine
™
 HIV-1/2 and Trinity Biotech 
Uni-Gold
™
 HIV) was performed according to WHO guidelines.
17
 Rapid diagnostic test for 
malaria (Paracheck Pf
®) was also performed in accordance with the manufacturer’s 
instructions. 
Climatic data. 
Data on rainfall (millimeters), temperature (degree Celsius), and relative humidity 
(percentage) were obtained from the Malawi Department of Climate Change and 
Meteorological Services for 2011–2013. 
Statistical analysis. 
Analysis was performed using Stata (Version 12.0; StataCorp Limited, College Station, 
TX). Monthly mean temperature, rainfall, and relative humidity were plotted against the 
number and proportion of influenza-positive SARI cases over the surveillance period to 
assess the association between climatic variations and influenza activity. 
Numerators for minimum adult influenza-associated SARI incidence estimates were 
generated from the number of enrolled SARI with a positive influenza PCR that resided in 
the Blantyre district and adjusted for non-enrolment (during weekends and outside of 
surveillance hours on weekdays) by multiplying by the reciprocal of the proportion of 
recruited cases among all SARI cases attending the emergency department. The latter was 
recorded on the Surveillance Program of Inpatients and Epidemiology (SPINE) electronic 
data collection system.
13
 The annual incidence of hospital-attended influenza-positive SARI 
per 100,000 persons was estimated using the adjusted number of medically attended 
influenza-positive SARIs, divided by the census estimates of Blantyre District population 
aged  15 years for each year,18 and multiplied by 100,000. Incidence by HIV status was also 
calculated for individuals aged 15–49 years (in whom HIV prevalence is available18). Human 
immunodeficiency virus–associated incidence rate ratios (IRRs) were calculated by dividing 
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the incidence in HIV-infected strata by the incidence in HIV-uninfected strata. 95% 
Confidence intervals (CIs) for incidence estimates and HIV-associated IRRs were calculated 
using the Poisson distribution. 
Logistic regression was used to calculate odds ratios (OR) and 95% CIs to compare 
clinical variables between influenza-positive and influenza-negative patients. Multivariable 
logistic regression models were developed for two outcomes of interest: 1) influenza 
positivity and 2) clinical severity (defined as Modified Early Warning Score (MEWS) > 4).
19
 
Modified early warning score is a simple physiological score based on five parameters 
(respiratory rate, heart rate, systolic blood pressure, temperature, and conscious level). It has 
been widely used in developed health-care settings to identify patients at risk of deterioration. 
A score of greater than 4 has been shown to be predictive of inpatient mortality in both well-
resourced
19,20
 and African settings.
21,22
 Covariates with a P value of < 0.2 on univariable 
analysis, in addition to age, gender, and year of surveillance considered a priori confounders, 
were assessed for significance using backward stepwise selection. Odds ratios and 95% CIs 
were reported. Factors with 2-sided P values of < 0.05 were considered significant. 
Ethics approval. 
Ethical approval for this study was obtained from the University of Malawi College of 
Medicine Research Ethics Committee (P.07/10/958), Liverpool School of Tropical Medicine 
(10.76), and the CDC through an ethical reliance. All participants provided written informed 
consent. 
RESULTS 
Demographic characteristics. 
Between January 2011 and December 2013, 1,126 SARI cases aged 15 years and older 
were enrolled (Table 1). The median age was 33 years (interquartile range 26–42 years) and 
489 (43.4%) were male. Of 1,109 patients with available HIV status (98.5%), 558 (50.3%) 
were HIV infected. Thirteen individuals reported receipt of influenza vaccination in the 
previous year. 
Viruses detected among SARI patients. 
One or more respiratory viruses were identified in 533 (47.3%) enrolled SARI cases 
(Table 1). Influenza viruses were detected in 163 (14.5%) SARI cases. When tested for the 
extended panel of respiratory viruses (N = 1,123) (Figure 1), rhinovirus was detected in 149 
(13.3%), coronavirus OC43 in 49 (4.4%), RSV in 48 (4.2%), and adenovirus in 47 (4.2%). 
Influenza A and B were detected more frequently in HIV-uninfected than in HIV-infected 
SARI cases (influenza A, 12.0% versus 8.2%; influenza B 6.0% versus 3.1%; Supplemental 
Table 1), whereas the prevalence of other respiratory viruses did not differ by HIV status. 
A single virus was isolated in 253 (22.5%) patients, whereas 154 (13.7%) individuals had 
two or more viruses detected. The highest proportion of viral co-detection was observed for 
bocavirus (21/24, 87.5%) and enterovirus (27/32; 84.4%), whereas the lowest proportion was 
observed in influenza A (26/108; 24.1%). 
Seasonality of influenza virus and malaria. 
Among the 163 influenza-positive SARI cases, 61 (37.2%) were influenza 
A(H1N1)pdm09, 47 (28.7%) were influenza A(H3N2), and 59 (30.5%) were influenza B. 
Three cases had influenza A and B coinfection and one influenza A sample was unsubtyped. 
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Figure 2 illustrates the temporal distribution of influenza types and subtypes, as well as 
malaria RDT positivity. There were annual cycles of influenza activity, but timing of peak 
detection varied year to year. In 2011, influenza activity had a bimodal peak—in April and 
July. In 2012, influenza was detected between March and June only. By contrast, influenza 
was detected throughout 2013 but peaked in January and February. Peaks in influenza 
activity coincided with months with high relative humidity, but there was no correlation with 
rainfall or temperature (Supplemental Figure 1A–C). Influenza A(H1N1)pdm09, A(H3N2), 
and influenza B circulated in all 3 years; influenza A(H1N1)pdm09 was the predominant 
strain in 2011 (39.1%) and 2013 (49.4%), whereas influenza A(H3N2) was the most 
prevalent in 2012 (48.6%). 
Of 911 SARI cases with available malaria RDT result, 28 (3.1%) were positive. There 
was no correlation between influenza and malaria activity (Figure 2). None of the cases with 
malaria were positive for influenza. 
Incidence estimates for hospital-attended influenza-positive SARIs. 
The mean annual incidence of hospital-attended influenza-positive SARI per 100,000 for 
Blantyre residents aged 15 years and older was 14.4 per 100,000 (95% CI: 12.9–16.0) [16.8 
(95% CI: 13.8–19.8) in 2011, 9.7 (95% CI: 7.4–11.9) in 2012, and 16.9 (95% CI: 140–19.8) 
in 2013]. 
Among individuals aged 15–49 years, the mean annual incidence of hospital-attended 
influenza-positive SARI in HIV-infected adults was 46.2 (95% CI: 37.5–56.3) per 100,000 
and 9.4 (95% CI: 8.1–10.9) per 100,000 in HIV-uninfected adults (IRR: 4.92, 95% CI: 3.83–
6.31). 
Factors associated with influenza positivity in SARI patients. 
Compared with influenza-negative patients, a higher proportion of influenza-positive 
SARI patients reported headache (90.1 versus 83.6%, OR: 1.79, 95% CI: 1.02–3.13, P = 
0.04). No other clinical feature differences by etiology were found (see Supplemental Table 
2). 
In the multivariable analysis (Table 2), female gender was associated with increased odds 
of influenza positivity compared with male gender (adjusted OR [aOR]: 1.57 (95% CI: 1.10–
2.26). Greater influenza activity was observed in the hot, rainy season (17.5%; aOR: 2.82, 
95% CI: 1.57–5.06) and the cold, dry season (16.5%; aOR: 2.37, 95% CI: 1.35–4.15), 
compared with the hot, dry season (6.7%). Furthermore, influenza positivity was inversely 
associated with HIV infection (aOR: 0.53, 95% CI: 0.36–0.76, P < 0.001) and co-detection 
with another respiratory virus (aOR: 0.46, 95% CI: 0.31–0.70, P < 0.001). Small numbers 
prohibited the evaluation of specific viral co-detection combinations with influenza. 
Factors associated with clinical severity. 
We found that 238 of 1,126 patients with SARI (21.1%) had clinically severe disease 
(MEWS > 4). In multivariable analysis (Table 3), HIV infection was associated with a nearly 
2-fold increase in clinical severity (aOR: 1.86, 95% CI: 1.35–2.56). SARI cases recruited in 
the hot, rainy season had five times increased odds of clinical severity, compared with those 
recruited in the hot, dry season (aOR: 4.98, 95% CI: 3.17–7.81). A higher proportion of 
clinically severe cases was also seen among cases recruited in 2011 (31.1 versus 17.9%, aOR: 
2.31, 95% CI: 1.59–3.36, compared with cases recruited in 2013). Influenza infection was not 
associated with severe clinical presentation, nor were infection with other respiratory viruses, 
or viral coinfection. 
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Among the 163 influenza-positive SARI cases, 40 (24.5%) had a MEWS > 4. Those 
infected with influenza A(H1N1)pdm09 subtype were significantly associated with clinical 
severity (64.1%; aOR: 5.40, 95% CI: 1.88–15.53) compared with those infected with 
influenza B (20.5%; aOR: 1.55, 95% CI: 0.47–5.06) and influenza A(H3N2) (15.4%; 
baseline). Human immunodeficiency virus infection also predicted severity among influenza-
positive SARI cases (38.3% versus 16.7%; aOR: 3.73, 95% CI: 1.65–8.41) (Supplemental 
Table 3). 
DISCUSSION 
Comprehensive hospital-based sentinel surveillance in our high HIV prevalence, malaria-
endemic African setting has identified influenza as an important contributor to SARI in 
adults, substantiating data from other African studies.
9,10
 In the immediate post-pandemic 
period, influenza A(H1N1)pdm09 was the predominant strain in Malawi in 2011 and 2013 
and was associated with increased clinical severity compared with other subtypes. Influenza 
activity corresponded to months with higher relative humidity, but not with malaria activity. 
Among adults with SARI, female gender, in addition to recruitment in hot, rainy and cool, 
dry seasons, were associated with influenza positivity. Although HIV-infected adults with 
SARI were more likely to have an alternative etiology to influenza, HIV-infected adults aged 
15–49 years had a 5-fold greater incidence of hospital-attended influenza-positive SARI 
compared with HIV-uninfected adults. Furthermore, HIV infection predicted clinical severity 
in all-cause SARI and influenza-associated SARI. 
The estimated annual incidence of hospital-attended influenza-positive SARI ranged from 
9.7 to 16.9 per 100,000 adult population, similar to that reported in rural Kenya (0.3/1,000)
23
 
but substantially lower than estimates by another Kenyan study (2.8/100 for influenza A and 
0.2/100 for influenza B
9
) and a South African study (71–260/100,000 [in HIV-infected 
persons] and 5–44/100,000 [in HIV-uninfected persons]).24 This wide variation could be due 
to geographical and seasonal differences in disease burden, but is also likely attributable to 
varying methodologies and case definitions, in addition to differing health-seeking behavior 
and thresholds for hospital admission. Furthermore, the latter two studies included children 
aged 5–14 years, a group that typically has higher rates of influenza infection.9,24 It is 
important to stress that our incidence estimates represent minimum estimates because our 
surveillance only detected persons accessing care at QECH. A small proportion of patients 
may have presented to a traditional healer or to one of the two private hospitals in Blantyre; 
SARI cases may not consider their symptoms severe enough to warrant care; they may be too 
ill or too poor to attend, or may have died before presentation.
25
 
Human immunodeficiency virus infection, identified in more than 50% of adults with 
SARI, was the sole individual risk factor associated with increased clinical severity. Indeed, 
several African adult pneumonia cohorts have reported a high prevalence of HIV infection 
(52–94%).26–28 Our result supports findings from others that HIV is an important driver of 
severe respiratory infection,
29
 including influenza, in sub-Saharan Africa. 
Influenza was less commonly identified in HIV-infected compared with HIV-uninfected 
SARI cases. This likely reflects the different spectra of organisms affecting HIV-infected 
adults, with greater relative contribution of opportunistic pathogens such as Mycobacterium 
tuberculosis, Pneumocystis jirovecii, and Streptococcus pneumoniae, rather than a lower 
absolute risk. This has also been described in HIV-infected children
30
 and adults
10
 in South 
Africa. In fact, after taking into account population denominators, HIV-infected adults aged 
15–49 years had a 5-fold greater incidence of influenza-positive SARI than HIV-uninfected 
adults. Having comprehensively ascertained HIV status, our study corroborates with studies 
in Malawi, Kenya, and South Africa that have identified HIV as a major risk factor for 
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influenza burden
25
 and severe disease.
24,31,32
 These results suggest that early HIV testing and 
expanded access to antiretroviral treatment, in addition to targeted influenza vaccination, 
could potentially have a substantial impact on burden of SARI in urban Blantyre and other 
similar high HIV prevalence settings. Annual influenza vaccination is recommended for 
HIV-infected individuals.
3
 Influenza vaccination in HIV-infected adults is safe and effective 
(pooled efficacy 85%),
33
 but influenza vaccines are currently unavailable in most African 
countries.
4,34
 
SARI cases recruited in hot, rainy season were associated with a 5-fold increased odds of 
clinical severity, compared with those recruited in the hot, dry season. This was also observed 
in our pediatric surveillance.
16
 The reason for this is unclear but could be related to other 
unmeasured infections (we were unable to determine the presence of bacterial pathogens in 
our SARI cases), seasonal patterns of health-care utilization, and seasonal malnutrition. The 
hot, rainy season in Malawi coincides with the “lean” season before harvest.35 A recent case-
control study in Malawi identified food insecurity as a risk factor for influenza severity,
31
 
thus supporting our latter hypothesis. 
We identified at least one respiratory virus in nearly half of all SARI cases, higher than 
that described in South African adults,
10
 and in developed settings.
36,37
 Viral coinfections 
were common, occurring in 14% of adult SARI cases. We also found a nonsignificant trend 
toward increased severity in adults with viral coinfection (26.7% versus 20.3% with MEWS 
> 4, P = 0.11). There is growing recognition that viruses other than influenza, such as 
rhinovirus, adenovirus, hMPV, and parainfluenza viruses, can cause clinically severe disease. 
However, whereas the detection of influenza, RSV, and hMPV in adults with SARI likely 
indicates an etiologic role,
38,39
 the presence of other respiratory viruses is of uncertain 
significance, particularly as we did not enroll accompanying controls. Further understanding 
of the interactions and contribution of these viruses to severe respiratory disease will help to 
narrow the focus on pertinent targets for vaccine and antiviral development. 
Our study has a number of limitations. First, we conducted single-site hospital-based 
surveillance. Although there are no other large inpatient facilities in Blantyre, we have not 
sampled from elsewhere in Malawi. Second, limiting recruitment to the first four cases of the 
day could have resulted in selection bias because individuals who present to hospital at 
different times of the day may have varying characteristics, such as health-seeking behavior 
or distance of residence from hospital. Third as discussed earlier, patients with SARI could 
have sought health care in facilities other than QECH, leading to an underestimation of our 
influenza-associated SARI rates. Under-ascertainment of SARI cases and resultant 
underestimation of incidence were also possible if SARI cases were not systematically 
recorded onto SPINE. Fourth, although we had near-complete ascertainment of HIV status 
(98.5%), data on CD4
+
 cell count and antiretroviral treatment status were not available. 
Comorbidities were also poorly recorded; thus, we were unable to evaluate chronic lung 
disease as a potential risk factor for influenza or adjust for underlying comorbidities in the 
multivariable analysis for clinical severity. Last, data on hospitalization and mortality were 
not systematically captured. Instead, we used the MEWS score as a surrogate marker for 
clinical severity. The score has been widely used in developed health-care settings to identify 
patients at risk of deterioration, and a threshold of greater than four is predictive of inpatient 
mortality.
19
 It has also been validated in other African settings.
21,22
 
This study provides a baseline for understanding the complexities of SARI epidemiology 
in adults in Malawi and other similar settings. In this high HIV prevalence setting, respiratory 
viruses were commonly identified in adults with SARI and influenza has a prominent 
etiological role. Human immunodeficiency virus–infected adults are at particular risk of 
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severe disease and have a higher burden of influenza-associated SARI than HIV-uninfected 
individuals. Ongoing surveillance for influenza and other respiratory viruses, with specific 
focus on severe disease in high-risk groups such as HIV-infected individuals and pregnant 
women, and greater effort to capture outcome data are critical to further characterize disease 
burden in these high-risk groups to inform public policy decisions. Improved HIV testing and 
early ART initiation, as well as targeted influenza vaccination could potentially substantially 
reduce the burden of SARI in Malawi and other sub-Saharan African countries with high 
HIV prevalence. 
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FIGURE 1. Respiratory viruses* detected in adults with severe acute respiratory infection (SARI), Blantyre, 
Malawi, 2011–2013. hMPV = human metapneumovirus; RSV = respiratory syncytial virus. *Respiratory 
viruses in the 33-pathogen multiplex polymerase chain reaction (PCR) include adenovirus, bocavirus, 
coronaviruses (OC43, NL63, 229E and HKU1), enterovirus, human metapneumovirus, parainfluenza viruses 1–
4, respiratory syncytial virus, and rhinovirus. This figure appears in color at www.ajtmh.org. 
FIGURE 2. Seasonality of influenza for adults with severe acute respiratory infection (SARI), Blantyre, Malawi, 
2011–2013. This figure appears in color at www.ajtmh.org. 
TABLE 1 
Characteristics of adult patients with SARI, Blantyre, Malawi, 2011–2013 
Characteristic SARI cases (N = 1,126) n 
(%) 
Demographic characteristics  
 Male 489 (43.4) 
 Age group (years)  
  15–24 231 (20.5) 
  25–34 419 (37.2) 
  35–44 251 (22.3) 
   45 225 (20.0) 
Underlying medical conditions  
 HIV-positive* 558 (50.3) 
 Pregnant† 19/637 (3.0) 
 Current smoker 29 (2.8) 
 Antibiotics in the past 2 weeks 482 (46.5) 
 Reported influenza vaccination in the past year 13 (1.2) 
Infectious agent identified  
 Influenza virus (any type) 163 (14.5) 
  Influenza A  
   H1N1pdm09 61 (37.4) 
   H3N2 47 (28.8) 
   Unsubtyped‡ 1 (0.6) 
  Influenza B 50 (30.7) 
  Influenza A & B 3 (1.8) 
 Any virus detected§ 533 (47.3) 
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   2 viruses detected 154 (13.6) 
 Malaria RDT positive 28/911 (3.1) 
HIV = human immunodeficiency virus; RDT = rapid diagnostic test; SARI = severe acute respiratory illness. 
* HIV status–available for 1,109 patients. 
† Pregnancy status established by self-report. 
‡ Influenza A sample with cycle threshold values  40 that could not be subtyped. 
§ Infection with at least one of influenza; adenovirus; bocavirus; coronavirus OC43, NL63, 229E and HKU1; 
enterovirus; human metapneumovirus; parainfluenza virus 1, 2, 3, and 4; rhinovirus, or respiratory syncytial 
virus. 
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TABLE 2 
Factors associated with influenza PCR positivity in adults with SARI, Queen Elizabeth Central Hospital, Blantyre, Malawi, 2011–2013 
Characteristic Overall Influenza virus 
negative, N (%) 
Influenza virus 
positive, N (%) 
Univariable* Multivariable*† 
OR (95% CI) P value* OR (95% CI) 
P value* 
Gender 
 Male 489 431 (88.1) 58 (11.9) Ref – – – 
 Female 636 532 (83.5) 105 (16.5) 1.47 (1.04–2.07) 0.03 1.57 (1.10–2.26) 0.01 
Age group (years) 
 15–24 231 191 (82.7) 40 (17.3) 1.37 (0.89–2.11) 0.36 1.23 (0.78–1.95) 0.68 
 25–34 419 359 (85.7) 60 (14.3) 1.10 (0.75–1.60) – 1.06 (0.71–1.58) – 
  35 476 413 (86.8) 63 (13.2) Ref – Ref – 
Year of surveillance 
 2011 251 205 (81.7) 46 (18.3) 2.12 (1.32–3.41) – 2.85 (1.72–4.71) – 
 2012 366 331 (90.4) 35 (9.6) Ref – Ref – 
 2013 509 427 (83.9) 82 (16.1) 1.82 (1.19–2.77) 0.003 1.84 (1.17–2.87) < 0.001 
Season of recruitment 
 December–March (hot and rainy) 348 287 (82.5) 61 (17.5) 2.98 (1.71–5.17) < 0.001 2.82 (1.57–5.06) < 0.001 
 April–August (cool and dry) 508 424 (83.4) 84 (16.5) 2.77 (1.63–4.72) – 2.37 (1.35–4.15) – 
 September–November (hot and dry) 270 252 (93.3) 18 (6.7) Ref – Ref – 
HIV status 
 Negative 551 455 (82.6) 96 (17.4) Ref – Ref – 
 Positive 558 498 (82.3) 60 (10.8) 0.57 (0.40–0.81) 0.002 0.53 (0.36–0.76) < 0.001 
Medical history 
 Malaria RDT—negative 883 745 (84.3) 138 (15.6) – – – – 
  Positive 28 28 (100) 0 (0) – – – – 
 Recent antibiotics—no 556 474 (85.2) 82 (14.8) Ref – – – 
  Yes 481 411 (85.4) 70 (14.6) 0.98 (0.70–1.39) 0.93 – – 
 Current smoking—no 1,019 868 (85.1) 151 (14.8) Ref – – – 
  Yes 29 28 (96.5) 1 (3.5) 0.21 (0.03–1.52) 0.12 – – 
Co-detection with other respiratory virus(es) 
 No 717 593 (82.7) 124 (17.3) Ref – Ref – 
 Yes 409 370 (90.5) 39 (9.5) 0.50 (0.34–0.74) < 0.001 0.46 (0.31–0.70) < 0.001 
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CI = confidence interval; HIV = human immunodeficiency virus; OR = odds ratio; PCR = polymerase chain reaction; RDT = rapid diagnostic test; SARI = severe acute 
respiratory illness. 
* Logistic regression. 
† Backward stepwise approach, including a priori confounders (age, gender, HIV status, and year of surveillance) and all variables with P < 0.20 in univariate analysis 
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TABLE 3 
Factors associated with clinical severity (MEWS > 4) in adults with SARI, Blantyre, Malawi, 2011–2013 
Characteristic Number of cases with 
clinical severity N (%) 
Univariable* Multivariable*† 
OR (95% CI) P value OR (95% CI) 
P value 
Gender 
 Male 105/489 (21.5) Ref – Ref – 
 Female 133/636 (20.9) 0.97 (0.72–1.29) 0.82 0.93 (0.69–1.27) 0.65 
Age group (years) 
 15–24 46/231 (19.9) Ref – Ref – 
 25–34 87/419 (20.8) 1.05 (0.71–1.57) – 0.82 (0.53–1.26) – 
  35 105/476 (22.1) 1.11 (0.81–1.51) 0.80 0.96 (0.63–1.46) 0.55 
Year of surveillance 
 2011 78/251 (31.1) 2.07 (1.46–2.94) 0.001 2.31 (1.59–3.36) < 0.001 
 2012 69/366 (18.9) 1.07 (0.75–1.51) – 1.19 (0.82–1.72) – 
 2013 91/509 (17.9) Ref – Ref – 
Season 
 December–March (hot 
and rainy) 
125/348 (35.9) 4.32 (2.80–6.67) – 4.98 (3.17–7.81) < 0.001 
 April–August (cool and 
dry) 
82/508 (16.1) 1.48 (0.95–2.31) – 1.66 (1.05–2.63) – 
 September–November 
(hot and dry) 
31/270 (11.5) Ref – Ref – 
HIV status 
 Negative 91/551 (16.5) Ref – Ref – 
 Positive 143/558 (25.6) 1.74 (1.30–2.34) < 0.001 1.86 (1.35–2.56) < 0.001 
Medical history 
 Pregnancy–No 131/618 (21.2) Ref – – – 
  Yes 2/19 (10.5) 0.44 (0.10–1.92) 0.27 – – 
 Recent antibiotics–No 134/548 (24.5) Ref – – – 
  Yes 101/483 (20.9) 0.82 (0.61–1.10) 0.19 – – 
 Current smoker—no 224/946 (23.7) Ref – – – 
  Yes 14/102 (13.7) 0.25 (0.06–1.04) 0.06 – – 
 Malaria RDT—Negative 213/883 (24.1) Ref – – – 
  Positive 6/28 (21.4) 0.86 (0.34–2.14) 0.74 – – 
 Influenza—negative 198/962 (20.6) Ref – – – 
  Positive 40/163 (24.5) 1.25 (0.85–1.85) 0.25 – – 
Viral co-infections 
 No 198/976 (20.3) Ref – – – 
 Yes 40/150 (26.7) 1.37 (0.93–2.03) 0.11 – – 
Other respiratory viruses 
 Adenovirus—negative 228/1,076 (21.2) Ref – – – 
  Positive 10/47 (21.3) 1.01 (0.49–2.05) 0.99 – – 
 Bocavirus—negative 232/1,099 (21.1) Ref – – – 
  Positive 6/24 (25.0) 1.25 (0.49–3.17) 0.65 – – 
 Coronavirus      
  OC43—negative 225/1,074 (21.0) Ref – – – 
   Positive 13/49 (26.5) 1.36 (0.71–2.61) 0.35 – – 
  NL63—negative 227/1,086 (20.9) Ref – – – 
   Positive 11/37 (29.7) 1.60 (0.78–3.29) 0.20 – – 
  229E—negative 227/1,088 (20.9) Ref – – – 
   Positive 11/35 (31.4) 1.74 (0.84–3.60) 0.14 – – 
  HKU1—negative 220/1,063 (20.7) Ref – – – 
   Positive 7/40 (17.5) 0.81 (0.35–1.86) 0.62 – – 
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  Enterovirus—negative 236/1,091 (21.6) Ref – – – 
   Positive 2/32 (6.3) 0.24 (0.06–1.02) 0.05 – – 
  hMPV—negative 224/1,089 (20.6) Ref – – – 
   Positive 14/34 (41.2) 2.70 (1.34–5.44) 0.005 – – 
 Parainfluenza virus      
  1—Negative 230/1,095 (21.0) Ref – – – 
   Positive 8/28 (28.6) 1.50 (0.65–3.46) 0.34 – – 
  2—Negative 231/1,105 (20.9) Ref – – – 
   Positive 7/18 (38.9) 2.40 (0.92–6.28) 0.07 – – 
  3—Negative 234/1,100 (21.3) Ref – – – 
   Positive 4/23 (17.4) 0.78 (0.26–2.31) 0.65 – – 
  4—Negative 233/1,095 (21.3) Ref – – – 
   Positive 5/28 (17.9) 0.80 (0.30–2.14) 0.66 – – 
  RSV—negative 226/1,075 (21.0) Ref – – – 
   Positive 12/47 (25.0) 1.25 (0.64–2.45) 0.51 – – 
  Rhinovirus—negative 201/974 (20.6) Ref – – – 
   Positive 37/149 (24.8) 1.27 (0.85–1.90) 0.24 – – 
CI = confidence interval; HIV = human immunodeficiency virus; MEWS = modified early warning score; OR = 
odds ratio; RDT = rapid diagnostic test; RSV = respiratory syncytial virus; SARI = severe acute respiratory 
infection. 
* Logistic regression. 
† Backward stepwise approach, including a priori confounders (age, gender, HIV status, and year of. 
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Supplementary Table 1.  Prevalence of respiratory viruses by HIV status in Adults with Severe 
Acute Respiratory infection, Queen Elizabeth Central Hospital, Blantyre, Malawi, 2011 – 2013. 
 
 
  
Characteristic 
Number of cases (%) 
 
P-value* 
HIV-positive 
(n=556) 
HIV-negative  
(n=550)  
Adenovirus  23 (4.1) 22 (5.0) 0.91 
Bocavirus 14 (2.5) 10 (1.8) 0.42 
Coronavirus OC43 31 (5.6) 18 (3.3) 0.06 
Coronavirus NL63 21 (3.8) 14 (2.6) 0.24 
Coronavirus 229E 15 (2.7) 20 (3.6) 0.37 
Coronavirus HKU1 15/542 (2.8) 22/544 (4.0) 0.25 
Enterovirus 12 (2.2) 19 (3.5) 0.19 
Human metapneumovirus 22 (4.0) 12 (2.2) 0.09 
Influenza A 46 (8.2) 66 (12.0) 0.04 
Influenza B 17 (3.1) 33 (6.0) 0.02 
Parainfluenza virus 1 10 (1.8) 18 (3.3) 0.12 
Parainfluenza virus 2 10 (1.8) 8 (1.5) 0.65 
Parainfluenza virus 3 12 (2.2) 10 (1.8) 0.69 
Parainfluenza virus 4 8 (1.4) 15 (2.7) 0.13 
Respiratory syncytial virus 28 (5.0) 18 (3.3) 0.14 
Rhinovirus 68 (12.2) 80 (14.6) 0.26 
 
Abbreviations:  HIV, human immunodeficiency virus. 
Supplementary Table 2.  Clinical Characteristics by Influenza PCR Status in Adults with 
Severe Acute Respiratory infection, Queen Elizabeth Central Hospital, Blantyre, Malawi, 2011 
– 2013. 
 
Characteristic  Number of cases (%) with 
characteristic 
      
    OR (95% CI) 
 
P-
value*  
All SARI cases 
(n=1126) 
Influenza 
PCR positive 
(n=163) 
Influenza 
PCR negative 
(n=963) 
Symptoms      
Fever >38c 909/1120 (81.2) 138/162 (85.2) 771/958 (80.5) 1.39 (0.88-2.23) 0.16 
Cough 1016/1045 (97.2) 149/152 (98.0) 867/893 (97.1) 1.49 (0.45-4.99) 0.52 
Sore throat 687/1041 (66.0) 95/150 (63.3) 592/891 (66.5) 0.87 (0.61-1.25)  0.45 
Headache 884/1046 (84.5) 137/152 (90.1)  747/894 (83.6) 1.79 (1.02-3.13) 0.04 
Rhinorrhoea 762/1043 (73.1) 113/152 (74.3)  649/891 (72.8)  1.08 (0.72-1.60)  0.03 
Myalgia 884/1044 (84.6) 129/152 (84.9)  755/892 (84.6)  1.02 (0.63-1.64)  0.94 
Vomiting/diarrhoea 166/1044 (15.9) 19/151 (12.6) 147/892 (16.5) 0.73 (0.44-1.22) 0.23 
Signs      
Confused 21/1043 (2.0) 4/152 (2.6) 17/891 (1.9) 1.39 (0.46-4.19) 0.56 
Systolic BP <90mmHg 140/1043 (13.4) 26/159 (17.5)  114/894 (12.8)                       1.44 (0.91-2.30) 0.12 
Heart rate 
>120/minute 
407/1044 (39.0) 66/150 (44.0)  341/894 (38.1) 1.27 (0.90-1.80) 0.18 
Respiratory rate 
>30/minute 
479/1037 (46.1) 75/148 (50.3) 404/889 (45.4) 1.23 (0.87-1.74) 0.24 
Oxygen saturation 
<90% on air 
124/1048 (11.8) 21/150 (14.0) 103/898 (11.5) 1.25 (0.76-2.08) 0.37 
 
   
Abbreviations: PCR=polymerase chain reaction; OR, odds ratio; CI, confidence interval; BP, blood 
pressure 
Supplementary Table 3.  Factors associated with clinical severity (MEWS >4) in 
adults with influenza-associated severe acute respiratory infection (SARI), 
Blantyre, Malawi, 2011–2013. 
 
Characteristic Number of 
cases with 
clinical 
severity 
(n=40) (%) 
Univariablea  Multivariablea,b 
 
OR (95% CI) 
 
P-
value 
  
OR (95% CI) 
 
P-
value 
Sex       
  Male 10/58 (17.2) Ref     
  Female 30/106 (28.6) 1.92 (0.86-4.28) 0.11    
Age group (years)       
  15-24 7/40 (17.5) Ref     
  25-34 12/60 (20.0) 1.18 (0.42-3.31)     
  > 35 21/63 (33.0) 2.36 (0.89-6.21) 0.12    
Year of surveillance       
2011 15/46 (32.6) 2.90 (0.93-8.99)     
2012 5/35 (14.3) Ref     
2013 20/82 (24.4) 1.94 (0.66-5.66) 0.15    
Season       
Hot and rainy 27/61 (44.3) 13.50 (1.69-
106.96) 
<0.001    
Cold and dry 12/83 (14.2) 2.83 (0.34-23.30)     
Hot and dry 1/18 (5.6) Ref     
HIV status       
  Negative 16/96 (16.7)  Ref   Ref  
  Positive 23/60 (38.3) 3.11 (1.47-6.56) 0.003  3.72 (1.65-8.42) 0.002 
Medical history       
Pregnancy  - No 39/157 (24.8) Ref     
                   - Yes 1/6 (16.7) 0.61 (0.07-5.34) 0.65    
Recent antibiotics  – No 21/82 (25.6) Ref     
                                  – Yes  
19/70 (27.1) 
 
1.08 (.53-2.23) 
 
0.83 
   
Influenza subtype       
  A(pdm)09 25/61 (41.0) 4.75 (1.75-12.86)   5.40 (1.88-15.53)  
  A(H3N2) 6/47 (12.8) Ref   Ref  
  B 8/50 (16.0) 1.30 (.042-4.08) <0.001  1.55 (0.47-5.06) <0.001 
Co-detection with 
other respiratory 
virus(es) 
      
  No 30/124 (24.2) Ref     
  Yes 10/39 (25.6) 1.08 (0.47-2.47) 0.86    
 
OR – odds ratio, CI – confidence interval, HIV – human immunodeficiency virus. 
aLogistic regression. 
bBackward stepwise approach, including all variables with p<0.20 in univariate analysis.  
